Australia's most trusted
source of pharma news
Wednesday, 20 August 2025
Posted 18 August 2025 PM
Eli Lilly has started putting pressure on governments to increase the prices at which they subsidise drugs, in line with the US Administration's "most favoured nation" policy, but refrained from commenting on the implications for Australia.
Last Thursday Lilly issued a statement saying it was negotiating with European payers to raise prices, with the stated objective being to "more fairly share the costs of breakthrough medical research across developed countries".
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.